This review evaluates the cardiovascular effects of testosterone therapy in men with hypogonadism, highlighting mixed evidence on cardiovascular risks. It suggests that testosterone therapy is generally safe for cardiovascular health, particularly in middle-aged and older men, improving metabolic profiles without increasing major cardiovascular events. The therapy does, however, elevate hematocrit
